Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos files registration statement in the United States for a proposed global offering

Mechelen, Belgium; 15 April 2015 - Galapagos NV (Euronext: GLPG) announced
today that it filed a Registration Statement on Form F-1 with the U.S.
Securities and Exchange Commission for a proposed global offering of ordinary
shares, including ordinary shares in the form of American Depositary Shares

Galapagos' ordinary shares are currently listed on Euronext Amsterdam and
Euronext Brussels. Application has been made to list the ADSs to be offered
in the global offering on the NASDAQ Stock Market in the United States under
the symbol "GLPG." Within the framework of the contemplated transaction,
Galapagos expects to offer ordinary shares in Europe and countries outside of
the United States and Canada in a concurrent private placement. Investors
other than qualified investors under applicable law will not be eligible to
participate in this possible private placement.

Morgan Stanley, Credit Suisse, and Cowen and Company are acting as joint
book-running managers, and Nomura and Bryan, Garnier&Co. are acting as
co-managers, for the proposed global offering.

A registration statement relating to these securities has been filed with the
U.S. Securities and Exchange Commission but has not yet become effective.
The securities may not be sold, nor may offers to buy be accepted, prior to
the time the registration statement becomes effective.

The securities referred to in this release are to be offered only by means of
a prospectus. A copy of the preliminary prospectus, when available, can be
obtained from Morgan Stanley&Co. LLC, 180 Varick Street, 2nd Floor, New York,
NY 10014, United States, Attention: Prospectus Department; Credit Suisse
Securities (USA) LLC, One Madison Avenue, New York, NY 10010, United States,
Attention: Prospectus Department, or by telephone at +1 (800) 221-1037, or by
email at; or Cowen and Company, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717,
United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.

This press release does not constitute an offer to sell nor a solicitation of
an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About Galapagos

Galapagos(Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology
company specialized in the discovery and development of small molecule
medicines with novel modes of action, with a pipeline comprising three Phase
2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation, and
other indications. In the field of inflammation, AbbVie and Galapagos signed
a collaboration agreement for the development and commercialization
offilgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations
in the CFTR gene. PotentiatorGLPG1837is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205,a
first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently
being tested in a Phase 2 proof-of-concept trial in ulcerative colitis
patients. GLPG1690, a fully proprietary, first-in-class inhibitor of
autotaxin, has shown favorable safety in a Phase 1 trial and is expected to
enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group,
including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and facilities
in The Netherlands, France, and Croatia.


Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&IR
Tel: +31 6 2291 6240

Galapagos forward-looking statements

This release may contain forward-looking statements regarding the commercial
potential of our product candidates generally, all of which involve certain
risks and uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," "continues," "we believe," "we intend," as well as similar
expressions. Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by
such forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities, regulatory
approval requirements and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.